Celera Genomics and Abbott Announce Target Selection from Research Collaboration

19-Apr-2005

Celera Genomics Group, an Applera Corporation business, and Abbott announced that two Celera antigen targets have been selected for further investigation by Abbott for therapeutic development. These are the first targets to be selected for advancement in the strategic collaboration established last year between Celera Genomics and Abbott to discover, develop and commercialize therapies for the treatment of cancer.

Under the terms of the collaboration agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. The collaboration encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research at Celera Genomics. Any of these antigens may be selected by Abbott, and Celera Genomics may elect to jointly fund clinical development and commercialization of any resulting therapeutic products and would then share any financial returns resulting from commercialization. Abbott has responsibility for the commercialization of jointly funded collaboration products. Celera Diagnostics, a joint venture between Celera Genomics and the Applied Biosystems Group of Applera, retains certain diagnostic rights associated with selected targets.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous